Vizirianakis Ioannis S
Laboratory of Pharmacology, Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki, Thessaloniki GR-54124, Greece.
Pharmacogenomics. 2005 Oct;6(7):701-11. doi: 10.2217/14622416.6.7.701.
The genomic era is now a reality and the extraction of genomic information with a practical value in healthcare represents the next challenge following the completion of the Human Genome Project. To this end, the first pharmacogenomics test approved by the US Food & Drug Administration for assessing cytochrome P450 (CYP)2D6 and CYP2C19 genotype in the implementation of pharmacotherapy decisions in patients, is expected to improve pharmaceutical care outcomes, at least for drugs that are substrates or inhibitors of these enzymes. Furthermore, the progress already achieved and the experience gained in the fields of pharmacogenomics and personalized medicine has clearly demonstrated that an interdisciplinary approach could better serve the target of improving pharmacotherapy outcomes in routine clinical practice. Such an approach will obviously move drug prescription towards pharmacotyping, a stage where the drug selection and dosage process carried out by medical practitioners for any given patient will be advanced by genomic knowledge and information.
基因组时代已然成为现实，在医疗保健领域提取具有实用价值的基因组信息，是人类基因组计划完成后的下一个挑战。为此，美国食品药品监督管理局批准的首个药物基因组学检测，用于评估细胞色素P450（CYP）2D6和CYP2C19基因型，以指导患者药物治疗决策，有望改善药物治疗效果，至少对于那些是这些酶的底物或抑制剂的药物而言。此外，药物基因组学和个性化医疗领域已经取得的进展和积累的经验清楚地表明，跨学科方法能够更好地服务于在常规临床实践中改善药物治疗效果这一目标。这种方法显然会使药物处方走向药物分型阶段，在这个阶段，执业医师针对任何给定患者进行的药物选择和剂量确定过程将因基因组知识和信息而得到推进。
